MCRB
Price:
$0.7686
Market Cap:
$131.23M
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation...[Read more]
Industry
Biotechnology
IPO Date
2015-06-26
Stock Exchange
NASDAQ
Ticker
MCRB
According to Seres Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.92. This represents a change of 245.92% compared to the average of -0.56 of the last 4 quarters.
The mean historical PE Ratio of Seres Therapeutics, Inc. over the last ten years is -15.95. The current -1.92 PE Ratio has changed 1.10% with respect to the historical average. Over the past ten years (40 quarters), MCRB's PE Ratio was at its highest in in the June 2023 quarter at 3.29. The PE Ratio was at its lowest in in the March 2015 quarter at -59.09.
Average
-15.95
Median
-4.45
Minimum
-91.61
Maximum
-1.58
Discovering the peaks and valleys of Seres Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 643.27%
Maximum Annual PE Ratio = -1.58
Minimum Annual Increase = -83.55%
Minimum Annual PE Ratio = -91.61
Year | PE Ratio | Change |
---|---|---|
2023 | -1.58 | -33.91% |
2022 | -2.38 | -80.80% |
2021 | -12.42 | -45.06% |
2020 | -22.61 | 643.27% |
2019 | -3.04 | 63.44% |
2018 | -1.86 | -59.44% |
2017 | -4.59 | 6.53% |
2016 | -4.31 | -71.42% |
2015 | -15.07 | -83.55% |
2014 | -91.61 | -63.48% |
The current PE Ratio of Seres Therapeutics, Inc. (MCRB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.46
5-year avg
-8.41
10-year avg
-15.95
Seres Therapeutics, Inc.’s PE Ratio is less than Syros Pharmaceuticals, Inc. (-0.12), greater than Iovance Biotherapeutics, Inc. (-6.32), greater than Veracyte, Inc. (-328.98), less than NanoString Technologies, Inc. (-0.06), less than Fate Therapeutics, Inc. (-1.51),
Company | PE Ratio | Market cap |
---|---|---|
-0.12 | $7.87M | |
-6.32 | $2.61B | |
-328.98 | $3.07B | |
-0.06 | $5.07M | |
-1.51 | $260.82M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Seres Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Seres Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Seres Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Seres Therapeutics, Inc. (MCRB)?
What is the highest PE Ratio for Seres Therapeutics, Inc. (MCRB)?
What is the 3-year average PE Ratio for Seres Therapeutics, Inc. (MCRB)?
What is the 5-year average PE Ratio for Seres Therapeutics, Inc. (MCRB)?
How does the current PE Ratio for Seres Therapeutics, Inc. (MCRB) compare to its historical average?